drugset / Trial / NCT04119102

Duobrii in Combination With Biologics

NCT04119102

NaSingle-groupOpen-labelTreatment

Summary

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

Timeline

Start
2019-10-14
Primary completion
2020-08-01
Completion
2020-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Duobrii Unknown

Indications